Emma Therese Van Der Westhuizen

Emma Therese Van Der Westhuizen

Auto-generated profile, based on publicly available information

Emma Therese Van Der Westhuizen

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
MMMatthieu Masureel
Matthieu Masureel
YZYaozhong Zou
Yaozhong Zou
LPLouis-Philippe Picard
Louis-Philippe Picard
EWEmma van der Westhuizen
Emma van der Westhuizen
JMJacob P. Mahoney
Jacob P. Mahoney
BKBrian K. Kobilka
Brian K. Kobilka

29 January 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
EWEmma T. van der Westhuizen
Emma T. van der Westhuizen
KCK. H. Christopher Choy
K. H. Christopher Choy
CVCeline Valant
Celine Valant
SMSimon McKenzie-Nickson
Simon McKenzie-Nickson
SBSophie J. Bradley
Sophie J. Bradley
ACArthur Christopoulos
Arthur Christopoulos
The M1and M4muscarinic acetylcholine receptors (mAChRs) are highly pursued drug targets for neurological diseases, in particular for Alzheimer’s disease and schizophrenia. Due to high sequence homology, selective targeting of any of the M1-M5mAChRs through the endogenous ligand binding site has been notoriously difficult to achieve. With the discovery of highly subtype selective mAChR positive allosteric modulators in the new millennium, selectivity through targeting an allosteric binding site has opened new avenues for drug discovery programs. However, some hurdles remain to be overcome for these promising new drug candidates to progress into the clinic. One challenge is the potential for on-target side effects, such as for the M1mAChR where over-activation of the receptor by orthosteric or allosteric ligands can be detrimental. Therefore, in addition to receptor subtype selectivity, a drug candidate may need to exhibit a biased signaling profile to avoid such on-target adverse effects. Indeed, recent studies in mice suggest that allosteric modulators for the M1mAChR that bias signaling toward specific pathways may be therapeutically important. This review brings together details on the signaling pathways activated by the M1and M4mAChRs, evidence of biased agonism at these receptors, and highlights pathways that may be important for developing new subtype selective allosteric ligands to achieve therapeutic benefit.

9 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BBBesma Benredjem
Besma Benredjem
JGJonathan Gallion
Jonathan Gallion
DPDennis Pelletier
Dennis Pelletier
PDPaul Dallaire
Paul Dallaire
JCJohanie Charbonneau
Johanie Charbonneau
GPGraciela Pineyro
Graciela Pineyro
Signaling diversity of G protein-coupled (GPCR) ligands provides novel opportunities to develop more effective, better-tolerated therapeutics. Taking advantage of these opportunities requires identifying which effectors should be specifically activated or avoided so as to promote desired clinical responses and avoid side effects. However, identifying signaling profiles that support desired clinical outcomes remains challenging. This study describes signaling diversity of mu opioid receptor (MOR) ligands in terms of logistic and operational parameters for ten different in vitro readouts. It then uses unsupervised clustering of curve parameters to: classify MOR ligands according to similarities in type and magnitude of response, associate resulting ligand categories with frequency of undesired events reported to the pharmacovigilance program of the Food and Drug Administration and associate signals to side effects. The ability of the classification method to associate specific in vitro signaling profiles to clinically relevant responses was corroborated using β2-adrenergic receptor ligands.

30 May 2023 in eLife
Verified
Journal Article
Open access
ZVZiva Vuckovic
Ziva Vuckovic
JWJinan Wang
Jinan Wang
VPVi Pham
Vi Pham
JMJesse I Mobbs
Jesse I Mobbs
MBMatthew J Belousoff
Matthew J Belousoff
DTDavid Thal
David Thal
Allosteric modulation of G protein-coupled receptors (GPCRs) is a major paradigm in drug discovery. Despite decades of research, a molecular-level understanding of the general principles that govern the myriad pharmacological effects exerted by GPCR allosteric modulators remains limited. The M4 muscarinic acetylcholine receptor (M4 mAChR) is a validated and clinically relevant allosteric drug target for several major psychiatric and cognitive disorders. In this study, we rigorously quantified the affinity, efficacy, and magnitude of modulation of two different positive allosteric modulators, LY2033298 (LY298) and VU0467154 (VU154), combined with the endogenous agonist acetylcholine (ACh) or the high-affinity agonist iperoxo (Ipx), at the human M4 mAChR. By determining the cryo-electron microscopy structures of the M4 mAChR, bound to a cognate Gi1 protein and in complex with ACh, Ipx, LY298-Ipx, and VU154-Ipx, and applying molecular dynamics simulations, we determine key molecular mechanisms underlying allosteric pharmacology. In addition to delineating the contribution of spatially distinct binding sites on observed pharmacology, our findings also revealed a vital role for orthosteric and allosteric ligand–receptor–transducer complex stability, mediated by conformational dynamics between these sites, in the ultimate determination of affinity, efficacy, cooperativity, probe dependence, and species variability. There results provide a holistic framework for further GPCR mechanistic studies and can aid in the discovery and design of future allosteric drugs.

4 December 2022 in British Journal of Pharmacology
Verified
Journal Article
Closed access
HNHuong T. M. Nguyen
Huong T. M. Nguyen
EWEmma T. van der Westhuizen
Emma T. van der Westhuizen
CLChristopher J. Langmead
Christopher J. Langmead
ATAndrew B. Tobin
Andrew B. Tobin
PSPatrick M Sexton
Patrick M Sexton
CVCeline Valant
Celine Valant